Evidence map›Paper›PMID 38704257›Full record

ArticleVaccine2024

Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.

Marine Maurel, Clara Mazagatos, Luise Goerlitz, Beatrix Oroszi, Mariette Hooiveld, Ausenda Machado, Lisa Domegan, Maja Ilić, Rodica Popescu, Noémie Sève and 21 more

Abstract readMulticenter Study
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Improved Methods for Vaccine Effectiveness Studies.The Journal of infectious diseases · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Marine MaurelEpiconcept, Paris, France.
Clara MazagatosNational Centre of Epidemiology, CIBERESP, Carlos III Health Institute, Madrid, Spain.
Luise GoerlitzDepartment for Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany.
Beatrix OrosziNational Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.
Mariette HooiveldNivel, Utrecht, the Netherlands.
Ausenda MachadoInstituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.
Lisa DomeganHSE-Health Protection Surveillance Centre, Dublin, Ireland.
Maja IlićCroatian Institute of Public Health, Zagreb, Croatia.
Rodica PopescuNational Institute of Public Health, Bucharest, Romania.
Noémie SèveSorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
Iván Martínez-BazInstituto de Salud Pública - IdiSNA- CIBERESP, Pamplona, Spain.
Amparo LarrauriNational Centre of Epidemiology, CIBERESP, Carlos III Health Institute, Madrid, Spain.
Silke BudaDepartment for Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany.
Gergő TúriNational Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.
Adam MeijerNational Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Verónica GomezInstituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.
Joan O'DonnellHSE-Health Protection Surveillance Centre, Dublin, Ireland.
Ivan MlinarićCroatian Institute of Public Health, Zagreb, Croatia.
Olivia Timnea"Cantacuzino" National Military Medical Institute for Research and Development, Bucharest, Romania.
Ana Ordax DiezInstituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL). Consejería de Sanidad. Junta de Castilla y León, Valladolid, Spain.
Ralf DürrwaldNational Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany.
Judit Krisztina HorváthNational Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.
Frederika DijkstraNational Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Ana Paula RodriguesInstituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal.
Adele McKennaHSE-Health Protection Surveillance Centre, Dublin, Ireland.
Sanja Kurečić FilipovićCroatian Institute of Public Health, Zagreb, Croatia.
Mihaela Lazar"Cantacuzino" National Military Medical Institute for Research and Development, Bucharest, Romania.
Marlena KaczmarekEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.
Sabrina BacciEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.
Esther KisslingEpiconcept, Paris, France.
VEBIS study team

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWithin influenza vaccine effectiveness (VE) studies at primary care level with a laboratory-confirmed outcome, clinical case definitions for recruitment of patients can vary. We used the 2022-23 VEBIS primary care European multicentre study end-of-season data to evaluate whether the clinical case definition affected IVE estimates.

methodsWe estimated VE using a multicentre test-negative case-control design. We measured VE against any influenza and influenza (sub)types, by age group (0-14, 15-64, ≥65 years) and by influenza vaccine target group, using logistic regression. We estimated IVE among patients meeting the European Union (EU) acute respiratory infection (ARI) case definition and among those meeting the EU influenza-like illness (ILI) case definition, including only sites providing information on specific symptoms and recruiting patients using an ARI case definition (as the EU ILI case definition is a subset of the EU ARI one).

resultsWe included 24 319 patients meeting the EU ARI case definition, of whom 21 804 patients (90 %) meet the EU ILI case definition, for the overall pooled VE analysis against any influenza. The overall and influenza (sub)type-specific VE varied by ≤2 % between EU ILI and EU ARI populations. DISCUSSION: Among all analyses, we found similar VE estimates between the EU ILI and EU ARI populations, with few (10%) additional non-ILI ARI patients recruited. These results indicate that VE in the 2022-23 influenza season was not affected by use of a different clinical case definition for recruitment, although we recommend investigating whether this holds true for next seasons.

Indexed as

Influenza, HumanInfluenza VaccinesPrimary Health CareVaccine EfficacyAdolescentAdultAgedCase-Control StudiesChildChild, PreschoolEuropeFemaleHumansInfantInfant, NewbornMaleInfluenza VaccinesClinical case definitionInfluenzaInfluenza vaccineMulticenter studyTest-negative designVaccine effectiveness

Identifiers

PMID38704257
PMCPMC11152456

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.